# 510(k) SUMMARY

This summary of $5 1 0 ( \mathbf { k } )$ safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR $\ S 8 0 7 . 9 2$ .

The Assigned 51o(k) Number is: K 08/922

Submitter:

Wallac Oy   
Mustionkatu 6   
20750 Turku, Finland   
Telephone: +358 2 2678111   
Fax: +358 2 2678357

Contact Person:

Katriina Suonpää Regulatory Affairs Manager katriina.suonpaa@perkinelmer.com

Date of Summary Prepared:

April 07, 2009

Device Name:

AutoDELFIA® Neonatal $1 7 \alpha$ -OH-progesterone kit

Classification Name:

Radioimmunoassay, 17-Hydroxyprogesterone Class I per 21 CFR $\ S 8 6 2 . 1 3 9 5$

Product Code:

JLX

Predicate Device:

AutoDELFIA® Neonatal $1 7 \alpha$ -OH-progesterone kit, 510(k) Number K042425

Device Description:

The AutoDELFIA Neonatal $1 7 \alpha$ -OH-progesterone (17-OHP) assay is a solid phase, time-resolved fluoroimmunoassay based on the competitive reaction between europium-labeled 17-OHP and sample 17-OHP for a limited amount of binding sites on 17-OHP specific polyclonal antibodies (derived from rabbit). Danazol facilitates the release of 17-OHP from the binding proteins. A second antibody, directed against rabbit IgG, is coated to the solid phase, giving convenient separation of the antibody-bound and free antigen.

Enhancement Solution dissociates europium ions from the labeled antigen into solution where they form highly fluorescent chelates with components of the Enhancement Solution. The fluorescence in each well is then measured. The fluorescence of each sample is inversely proportional to the concentration of 17-OHP in the sample.

Intended Use:

The AutoDELFIA Neonatal $1 7 \alpha$ -OH-progesterone kit is intended for the quantitative determination of human $1 7 \alpha$ -OH-progesterone in blood specimens dried on filter paper as an aid in screening newborns for congenital adrenal hyperplasia (CAH) using the 1235 AutoDELFIA automatic immunoassay system.

Substantial Equivalence:

The AutoDELFIA Neonatal $1 7 \alpha$ -OH-progesterone kit (B024) is substantially equivalent to our currently marketed AutoDELFIA Neonatal $1 7 \alpha$ -OH-progesterone kit (B015) (K042425). The primary difference is a new antiserum in B024. The new antiserum has less crossreactivity with the physiologically important steroids in neonates, making it more specific for measuring $1 7 { \alpha } { \cdot } \mathrm { O H } { - }$ progesterone. There are the following similarities and differences between the two kits:

Table 1. Characteristics of the two kits.   

<table><tr><td colspan="1" rowspan="1">Characteristic</td><td colspan="1" rowspan="1">Proposed DeviceAutoDELFIA Neonatal17α-OH-progesterone kitB024</td><td colspan="1" rowspan="1">Predicate DeviceAutoDELFIA Neonatal17α-OH-progesterone kitB015</td></tr><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Intended User</td><td colspan="1" rowspan="1">Adequately trained laboratorypersonnel in laboratories performingnewborn screening</td><td colspan="1" rowspan="1">Adequately trained laboratorypersonnel in laboratories performingnewborn screening</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">Quantitative determination of 17α-OH-progesterone in blood specimensdried on filter paper</td><td colspan="1" rowspan="1">Quantitative determination of 17α-OH-progesterone in blood specimensdried on filter paper</td></tr><tr><td colspan="1" rowspan="1">Indication for Use</td><td colspan="1" rowspan="1">An aid in screening newborns forcongenital adrenal hyperplasia</td><td colspan="1" rowspan="1">An aid in screening newborns forcongenital adrenal hyperplasia</td></tr><tr><td colspan="1" rowspan="1">Chemical Principle</td><td colspan="1" rowspan="1">Competitive reaction betweeneuropium labeled 17-OHP andsample 17-OHP for a limited numberof binding sites on 17-OHP specificpolyclonal antibodies derived fromrabbit</td><td colspan="1" rowspan="1">Competitive reaction betweeneuropium labeled 17-OHP andsample 17-OHP for a limited numberof binding sites on 17-OHP specificpolyclonal antibodies derived fromrabbit</td></tr><tr><td colspan="1" rowspan="1">Assay Principle</td><td colspan="1" rowspan="1">Time-resolved fluoroimmunoassay</td><td colspan="1" rowspan="1">Time-resolved fluoroimmunoassay</td></tr><tr><td colspan="1" rowspan="1">Instrument</td><td colspan="1" rowspan="1">1235 AutoDELFIA automaticimmunoassay system</td><td colspan="1" rowspan="1">1235 AutoDELFIA automaticimmunoassay system</td></tr><tr><td colspan="1" rowspan="1">Detection principle</td><td colspan="1" rowspan="1">Time-resolved fluorescence</td><td colspan="1" rowspan="1">Time-resolved fluorescence</td></tr><tr><td colspan="1" rowspan="1">Specimen</td><td colspan="1" rowspan="1">Filter paper disks with a diameter ofapproximately 3.2 mm (1/8 inch)</td><td colspan="1" rowspan="1">Filter paper disks with a diameter ofapproximately 3.2 mm (1/8 inch)</td></tr><tr><td colspan="1" rowspan="1">Calibrator andControl Matrix</td><td colspan="1" rowspan="1">Human blood with a hematocrit of50-55% and spotted onto filter papercassettes (Whatman Grade 903)</td><td colspan="1" rowspan="1">Human blood with a hematocrit of50-55% and spotted onto filter papercassettes (Whatman Grade 903)</td></tr><tr><td colspan="1" rowspan="1">Calibration</td><td colspan="1" rowspan="1">Calibrated using gravimetric methods</td><td colspan="1" rowspan="1">Calibrated using gravimetric methods</td></tr><tr><td colspan="1" rowspan="1">Controls</td><td colspan="1" rowspan="1">3 levels (approx. values 17, 45 and100 ng/mL serum)</td><td colspan="1" rowspan="1">3 levels (approx. values 17, 45 and100 ng/mL serum)</td></tr><tr><td colspan="1" rowspan="1">Assay Buffer</td><td colspan="1" rowspan="1">17-OHP Assay Buffer, ready for use</td><td colspan="1" rowspan="1">17-OHP Assay Buffer, ready for use</td></tr><tr><td colspan="1" rowspan="1">Coated Plates</td><td colspan="1" rowspan="1">Anti-rabbit IgG Microtitration Strips,8 x 12 wells coated with anti-rabbitIgG (raised in goat)</td><td colspan="1" rowspan="1">Anti-rabbit IgG Microtitration Strips,8 x 12 wells coated with anti-rabbitIgG (raised in goat)</td></tr><tr><td colspan="1" rowspan="1">Characteristic,continued</td><td colspan="1" rowspan="1">Proposed DeviceAutoDELFIA Neonatal17α-OH-progesterone kitB024</td><td colspan="1" rowspan="1">Predicate DeviceAutoDELFIA Neonatal17α-OH-progesterone kitB015</td></tr><tr><td colspan="3" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Antibodies</td><td colspan="1" rowspan="1">Rabbit polyclonal antibodies</td><td colspan="1" rowspan="1">Different rabbit polyclonalantibodies</td></tr><tr><td colspan="1" rowspan="1">AntibodyCross-Reactionsin the Assay</td><td colspan="1" rowspan="1">17α-OH pregnenolone sulfate0.78 %11-Deoxycortisol 0.62 %17α-OH pregnenolone 0.83 %Progesterone 0.37 %</td><td colspan="1" rowspan="1">17α-OH pregnenolone sulfate2.0 %11-Deoxycortisol 1.82 %17α-OH pregnenolone 1.20 %Progesterone 0.47 %</td></tr><tr><td colspan="1" rowspan="1">Tracer</td><td colspan="1" rowspan="1">17-OHP-Eu tracer stock solution,approximate concentration of40 nmol/L, lyophilized</td><td colspan="1" rowspan="1">17-OHP-Eu tracer stock solution,approximate concentration of250 nmol/L, lyophilized</td></tr><tr><td colspan="1" rowspan="1">Calibrators</td><td colspan="1" rowspan="1">6 levels(approx. values 0, 4, 10, 25, 75,and 220 ng/mL serum)</td><td colspan="1" rowspan="1">6 levels(approx. values 0, 10, 25, 50, 100and 250 ng/mL serum)</td></tr><tr><td colspan="1" rowspan="1">Analytical Sensitivity /Limit of Blank,Limit of Detection,Limit of Quantitation</td><td colspan="1" rowspan="1">Limit of Blank0.37 ng/mL serumLimit of Detection0.84 ng/mL serumLimit of Quantitation1.4 ng/mL serum</td><td colspan="1" rowspan="1">Analytical Sensitivity(Limit of Blank) 1.3 ng/mL serum</td></tr><tr><td colspan="1" rowspan="1">Precision (TotalVariation using a fullcalibration curve oneach plate)</td><td colspan="1" rowspan="1">2.12 ng/mL serum CV% 13.04.69 ng/mL serum CV% 9.87.52 ng/mL serum CV% 14.827.0 ng/mL serumCV% 8.354.4 ng/mL serumCV% 9.2109 ng/mL serum CV% 10.8182 ng/mL serum CV%9.1</td><td colspan="1" rowspan="1">25.9 ng/mL serum CV% 13.253.0 ng/mL serum CV% 10.8114 ng/mL serum CV% 10.9</td></tr><tr><td colspan="1" rowspan="1">Precision (TotalVariation using onecalibration curve forevery batch of 4 plates)</td><td colspan="1" rowspan="1">2.25 ng/mL serum CV% 14.04.89 ng/mL serum CV% 12.07.79 ng/mL serum CV% 15.827.7 ng/mL serum CV% 9.755.7 ng/mL serum CV% 10.5113 ng/mL serumCV% 12.7188 ng/mL serumCV% 11.3</td><td colspan="1" rowspan="1">25.8 ng/mL serum CV% 14.052.9 ng/mL serum CV% 12.4115 ng/mL serum CV% 11.8</td></tr><tr><td colspan="1" rowspan="1">Median Values inNewborn Screening(Study 1)</td><td colspan="1" rowspan="1">&lt; 1250 g20.9 ng/mL serum1250-2249 g 9.7 ng/mL serum≥ 2250 g 6.7 ng/mL serum</td><td colspan="1" rowspan="1">&lt; 1250 g 35.6 ng/mL serum1250-2249 g 20.0 ng/mL serum≥ 2250 g  14.1 ng/mL serum</td></tr><tr><td colspan="1" rowspan="1">Median Values inNewborn Screening(Study 2)</td><td colspan="1" rowspan="1">&lt;1250 g 13.3 ng/mL serum1250-2249 g 12.1 ng/mL serum≥ 2250 g  7.1 ng/mL serum</td><td colspan="1" rowspan="1">&lt; 1250 g  30.2 ng/mL serum1250-2249 g 23.4 ng/mL serum≥2250 g  13.7 ng/mL serum</td></tr></table>

# Screening Efficacy:

The proposed kit and the predicate device were compared in two newborn screening laboratories using retrospective specimens and excess samples. A number of known CAH cases were included. The results categorizing the number of evaluation samples according to screening outcome are shown in Tables 2-7 (Study 1) and in Tables 8-13 (Study 2).

# Study 1, Tables 2 - 7:

In total, 17 confirmed CAH case samples were available for the study. All of them were retrospective samples.

Table 2. Screening results and true diagnosis in the $< l 2 5 0 g$ weight category, $g \mathcal { O } ^ { t h }$ EMP percentile.   

<table><tr><td rowspan=1 colspan=1>New kit B024Cut-off56.7 ng/mL</td><td rowspan=1 colspan=1>Old kit B015Cut-off135 ng/mL</td><td rowspan=1 colspan=1>TotalSubjects</td><td rowspan=1 colspan=1>DiagnosedCAH</td><td rowspan=1 colspan=1>No diagnosedCAH</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>30</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>7</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>7</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>319</td><td rowspan=1 colspan=1>1*</td><td rowspan=1 colspan=1>318</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>364</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>362</td></tr></table>

Table 3. Screening results and true diagnosis in the $< l 2 5 0 g$ weight category, $9 5 ^ { t h }$ EPY percentile.   

<table><tr><td rowspan=1 colspan=1>New kit B024Cut-off73.6 ng/mL</td><td rowspan=1 colspan=1>Old kit B015Cut-off178 ng/mL</td><td rowspan=1 colspan=1>TotalSubjects</td><td rowspan=1 colspan=1>DiagnosedCAH</td><td rowspan=1 colspan=1>No diagnosedCAH</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>12</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>7</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>7</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>337</td><td rowspan=1 colspan=1>1*</td><td rowspan=1 colspan=1>336</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>364</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>362</td></tr></table>

\* In this case, the mother had CAH. Treatment for CAH includes lifetime daily medication, prednisone or dexamethasone. Because the specimen was taken during the first day of life, the mother's treatment would have impacted the 17-OHP test result of the infant.

Table 4. Screening results and true diagnosis in the 1250-2249g weight category, ${ g } { \boldsymbol { \theta } } ^ { t h }$ EY percentile.   

<table><tr><td rowspan=1 colspan=1>New kit B024Cut-off33.5 ng/mL</td><td rowspan=1 colspan=1>Old kit B015Cut-off76.9 ng/mL</td><td rowspan=1 colspan=1>TotalSubjects</td><td rowspan=1 colspan=1>DiagnosedCAH</td><td rowspan=1 colspan=1>No diagnosedCAH</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>37</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>15</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>13</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>433</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>433</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>498</td></tr></table>

Table 5. Screening results and true diagnosis in the $1 2 5 0 - 2 2 4 9 g$ weight category, $9 5 ^ { t h }$ percentile.   

<table><tr><td rowspan=1 colspan=1>New kit B024Cut-off40.8 ng/mL</td><td rowspan=1 colspan=1>Old kit B015Cut-off98.4 ng/mL</td><td rowspan=1 colspan=1>TotalSubjects</td><td rowspan=1 colspan=1>DiagnosedCAH</td><td rowspan=1 colspan=1>No diagnosedCAH</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>17</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>8</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>8</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>465</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>465</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>anmaGntlo</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>498</td></tr></table>

Table 6. Screening results and true diagnosis in th $e \geq 2 2 5 0 g$ weight category, ${ 9 0 } ^ { t h }$ EY percentile.   

<table><tr><td rowspan=1 colspan=1>New kit B024Cut-off14.3 ng/mL</td><td rowspan=1 colspan=1>Old kit B015Cut-off31.5 ng/mL</td><td rowspan=1 colspan=1>TotalSubjects</td><td rowspan=1 colspan=1>DiagnosedCAH</td><td rowspan=1 colspan=1>No diagnosedCAH</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+a$</td><td rowspan=1 colspan=1>119</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>106</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>28</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>26</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1155</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1155</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1328</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>1315</td></tr></table>

Table 7. Screening results and true diagnosis in t $h e \geq 2 2 5 0 g$ weight category, $9 5 ^ { t h }$ EY percentile.   

<table><tr><td rowspan=1 colspan=1>New kit B024Cut-off20.9 ng/mL</td><td rowspan=1 colspan=1>Old kit B015Cut-off49.0 ng/mL</td><td rowspan=1 colspan=1>Totalsubjects</td><td rowspan=1 colspan=1>DiagnosedCAH</td><td rowspan=1 colspan=1>No diagnosedCAH</td></tr><tr><td rowspan=1 colspan=1>$+ra}$</td><td rowspan=1 colspan=1>+$</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>49</td></tr><tr><td rowspan=1 colspan=1>+$</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>17</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>18</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1231</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1231</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1328</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>1315</td></tr></table>

# Study 2, Tables 8 - 13:

Confirmed CAH case samples were available only in the $\geq 2 2 5 0 \mathrm { g }$ birth weight category, in total 13 cases. All of them were retrospective samples.

Table 8. Screening results and true diagnosis in the $< l 2 5 0 g$ weight category, $9 \mathcal { O } ^ { t h }$ percentile.   

<table><tr><td rowspan=1 colspan=1>New kit B024Cut-off59.5 ng/mL</td><td rowspan=1 colspan=1>Old kit B015Cut-off125 ng/mL</td><td rowspan=1 colspan=1>TotalSubjects</td><td rowspan=1 colspan=1>DiagnosedCAH</td><td rowspan=1 colspan=1>No diagnosedCAH</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>15</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>149</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>149</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>168</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>168</td></tr></table>

Table 9. Screening results and true diagnosis in the $< 1 2 5 0 g$ weight category, $9 5 ^ { t h }$ EY percentile.   

<table><tr><td rowspan=1 colspan=1>New kit B024Cut-off95.0 ng/mL</td><td rowspan=1 colspan=1>Old kit B015Cut-off202 ng/mL</td><td rowspan=1 colspan=1>TotalSubjects</td><td rowspan=1 colspan=1>DiagnosedCAH</td><td rowspan=1 colspan=1>No diagnosedCAH</td></tr><tr><td rowspan=1 colspan=1>+$</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>155</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>155</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>168</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>168</td></tr></table>

Table 10. Screening results and true diagnosis in the 1250 - 2249g weight category, $g \mathcal { O } ^ { t h }$ percentile.   

<table><tr><td rowspan=1 colspan=1>New kit B024Cut-off54.3 ng/mL</td><td rowspan=1 colspan=1>Old kit B015Cut-off137 ng/mL</td><td rowspan=1 colspan=1>TotalSubjects</td><td rowspan=1 colspan=1>DiagnosedCAH</td><td rowspan=1 colspan=1>No diagnosedCAH</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>30</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>8</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>8</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>326</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>326</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>372</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>372</td></tr></table>

Table 11. Screening results and true diagnosis in the 1250 - 2249g weight category, $9 5 ^ { t h }$ percentile.   

<table><tr><td rowspan=1 colspan=1>New kit B024Cut-off68.6 ng/mL</td><td rowspan=1 colspan=1>Old kit B015Cut-off167 ng/mL</td><td rowspan=1 colspan=1>TotalSubjects</td><td rowspan=1 colspan=1>DiagnosedCAH</td><td rowspan=1 colspan=1>No diagnosedCAH</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>8</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+$</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>8</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>345</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>345</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>372</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>372</td></tr></table>

Table 12. Screening results and true diagnosis in the $\ge 2 2 5 0 g$ weight category, ${ g } { \boldsymbol { \theta } } ^ { t h }$ percentile.   

<table><tr><td rowspan=1 colspan=1>New kit B024Cut-off16.1 ng/mL</td><td rowspan=1 colspan=1>Old kit B015Cut-off32.9 ng/mL</td><td rowspan=1 colspan=1>TotalSubjects</td><td rowspan=1 colspan=1>DiagnosedCAH</td><td rowspan=1 colspan=1>No diagnosedCAH</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>121</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>108</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>21</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>21</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1136</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1136</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1299</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>1286</td></tr></table>

Table 13. Screening results and true diagnosis in $t h e \geq 2 2 5 0 g$ weight category, $9 5 ^ { t h }$ EPY percentile.   

<table><tr><td rowspan=1 colspan=1>New kit B024Cut-off28.3 ng/mL</td><td rowspan=1 colspan=1>Old kit B015Cut-off66.5 ng/mL</td><td rowspan=1 colspan=1>TotalSubjects</td><td rowspan=1 colspan=1>DiagnosedCAH</td><td rowspan=1 colspan=1>No diagnosedCAH</td></tr><tr><td rowspan=1 colspan=1>+$</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>56</td></tr><tr><td rowspan=1 colspan=1>+ra$</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>9</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1212</td><td rowspan=1 colspan=1>1*</td><td rowspan=1 colspan=1>1211</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1299</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>1286</td></tr></table>

\* Using percentiles higher than the $\overline { { 9 0 ^ { \mathfrak { t h } } } }$ percentile as the assay's cut-off resulted in one false negative result out of the 13 clinically confirmed CAH samples assayed. Laboratories should take this into consideration when setting their screening cut-offs.

Wallac Oy   
c/o Katriina Suonpää   
Regulatory Affairs Manager   
Mustionkatu 6   
20750 Turku, Finland

Re: k081922 Trade/Device Name: AutoDELFIA Neonatal $1 7 \alpha$ -OH-progesterone kit Regulation Number: 21 CFR 862.1395 Regulation Name: Radioimmunoassay, 17-Hydroxyprogesterone Regulatory Class: Class I, meets limitations of exemptions under 21 CFR $\ S$ 862.9 (c)(2) Product Code: JLX Dated: March 27, 2009 Received: April 2, 2009

Dear Katriina Suonpää:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class Ⅱ (Special Controls) or class Ⅲ (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page -. 2

This letter willallow you to begin marketing your device as described in your Section 510(k) premarket notification.The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address   
http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

![](images/4713e010b74fbf64cf27133770344bf1b9b274866009b631624ee900f1a8f45f.jpg)

Courtney C. Harper, Ph.D.   
Acting Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Indication for Use

510(k) Number (if known):

# K081922

Device Name:

AutoDELFIA® Neonatal 17α-OH-progesterone kit

Indication For Use:

The AutoDELFIA® Neonatal $1 7 a$ OH-progesterone kit is intended for the quantitative determination of human $1 7 \alpha \cdot$ - OH-progesterone in blood specimens dried on filter paper as an aid in screening newborns for congenital adrenal hyperplasia (CAH) using the 1235 AutoDELFIA® automatic immunoassay system.